YMAB Y-mAbs Therapeutics, Inc. Stock Quote

YMAB [NASD]

Index	-	P/E	-	EPS (ttm)	-2.67	Insider Own	0.50%	Shs Outstand	43.71M	Perf Week	11.01%
Market Cap	373.27M	Forward P/E	-	EPS next Y	-1.42	Insider Trans	-83.47%	Shs Float	38.32M	Perf Month	-20.45%
Income	-116.80M	PEG	-	EPS next Q	-0.69	Inst Own	63.20%	Short Float	7.53%	Perf Quarter	24.59%
Sales	40.00M	P/S	9.33	EPS this Y	57.00%	Inst Trans	-6.42%	Short Ratio	5.90	Perf Half Y	-48.08%
Book/sh	3.60	P/B	2.74	EPS next Y	11.50%	ROA	-51.70%	Target Price	28.17	Perf Year	-72.59%
Cash/sh	4.15	P/C	2.38	EPS next 5Y	-	ROE	-59.70%	52W Range	6.50 - 39.82	Perf YTD	-39.05%
Dividend	-	P/FCF	-	EPS past 5Y	-19.60%	ROI	-64.10%	52W High	-75.19%	Beta	1.40
Dividend %	-	Quick Ratio	5.90	Sales past 5Y	-	Gross Margin	89.90%	52W Low	52.00%	ATR	1.07
Employees	148	Current Ratio	6.10	Sales Q/Q	94.40%	Oper. Margin	-	RSI (14)	48.87	Volatility	10.05% 12.52%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-185.30%	Profit Margin	-	Rel Volume	0.80	Prev Close	9.52
Shortable	Yes	LT Debt/Eq	0.00	Earnings	May 09 AMC	Payout	-	Avg Volume	489.15K	Price	9.88
Recom	1.90	SMA20	3.16%	SMA50	-10.01%	SMA200	-45.45%	Volume	394,417	Change	3.78%

Feb-03-22

Resumed

Guggenheim

Buy

$22

Nov-19-21

Resumed

Morgan Stanley

Equal-Weight

$25

Nov-16-21

Downgrade

JP Morgan

Overweight → Neutral

$57 → $30

May-07-21

Upgrade

BofA Securities

Neutral → Buy

Apr-23-21

Resumed

Cowen

Outperform

Mar-22-21

Resumed

JP Morgan

Overweight

$57 → $52

Jan-15-21

Downgrade

BofA Securities

Buy → Neutral

$56

Nov-09-20

Reiterated

H.C. Wainwright

Buy

$52 → $65

May-05-20

Initiated

Barclays

Overweight

$44

May-01-20

Initiated

Janney

Buy

Apr-29-20

Initiated

Morgan Stanley

Equal-Weight

Dec-24-19

Initiated

JP Morgan

Overweight

$39

Nov-20-19

Initiated

Guggenheim

Buy

Sep-04-19

Initiated

Wedbush

Outperform

Apr-01-19

Initiated

H.C. Wainwright

Buy

$36

Oct-16-18

Initiated

BTIG Research

Buy

$35

Oct-16-18

Initiated

BofA/Merrill

Buy

$26

May-09-22 05:25PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates Zacks -7.22%
04:01PM	Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments GlobeNewswire
May-03-22 04:01PM	Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022 GlobeNewswire
Apr-28-22 03:02PM	Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline Zacks -8.66%
Apr-27-22 04:01PM	Y-mAbs Announces Executive Management Changes and Provides 2022 Revenue Guidance and Financial Update GlobeNewswire
Apr-21-22 08:16AM	Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation Simply Wall St. -5.56%
Apr-08-22 09:00AM	Y-mAbs Announces Presentation of SADA Technology at AACR GlobeNewswire
Apr-01-22 09:00AM	Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA GlobeNewswire +9.93%
Mar-21-22 10:14AM	YmAbs Therapeutics, Inc. (YMAB) Soars 11.3%: Is Further Upside Left in the Stock? Zacks
Mar-07-22 04:51AM	What Kind Of Shareholders Hold The Majority In Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Shares? Simply Wall St.
Feb-24-22 05:40PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates Zacks
04:01PM	Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments GlobeNewswire
Feb-17-22 03:02PM	Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline Zacks
09:00AM	Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022 GlobeNewswire
Feb-14-22 10:29AM	Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA Zacks -7.15%
Feb-11-22 09:00AM	Y-mAbs Announces Completion of Pre-BLA Meeting with FDA for Omburtamab GlobeNewswire +25.95%
Feb-01-22 08:11AM	YmAbs Therapeutics, Inc. (YMAB) Soars 8.3%: Is Further Upside Left in the Stock? Zacks
Jan-21-22 10:31AM	Investors one-year losses grow to 76% as the stock sheds US$69m this past week Simply Wall St. -7.01%
Jan-05-22 09:00AM	Y-mAbs Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire -8.41%
Dec-15-21 09:53AM	UPDATE - Y-mAbs Announces Pipeline Update GlobeNewswire +5.53%
09:00AM	Y-mAbs Announces Pipeline Update GlobeNewswire
Dec-06-21 04:05PM	Y-mAbs Hosting Virtual Research and Development Day GlobeNewswire
Nov-10-21 08:32PM	2 Strong Buy Stocks Flirting With a Bottom TipRanks
Nov-04-21 06:45PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Misses Revenue Estimates Zacks -14.33%
04:05PM	Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments GlobeNewswire
09:00AM	Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis GlobeNewswire
Oct-28-21 04:01PM	Y-mAbs to Announce Third 2021 Financial and Operating Results on November 4, 2021 GlobeNewswire
Oct-08-21 12:01PM	Here's Why We're Not Too Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Situation Simply Wall St.
Oct-07-21 09:00AM	Y-mAbs 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Granted Rare Pediatric Disease Designation by FDA GlobeNewswire
Sep-16-21 09:00AM	Y-mAbs Announces Data to be Presented at SIOP 2021 GlobeNewswire
Sep-13-21 09:00AM	Y-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China GlobeNewswire
Sep-10-21 09:00AM	Y-mAbs to Host Key Opinion Leader Webinar on DANYELZA® (naxitamab-gqgk) Frontline and HITS Data in High-Risk Neuroblastoma GlobeNewswire
Sep-08-21 07:54PM	Y-Mabs Therapeutics Trades $1.76 Million In Company Stock Benzinga
Aug-09-21 01:44AM	The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Second-Quarter Results Are Out And Analysts Have Published New Forecasts Simply Wall St.
Aug-05-21 06:05PM	YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:01PM	Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments GlobeNewswire
Jul-29-21 04:05PM	Y-mAbs to Announce Second Quarter 2021 Financial and Operating Results on August 5, 2021 GlobeNewswire
Jul-06-21 08:37AM	Y-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China GlobeNewswire -5.87%
Jun-25-21 09:00AM	Y-mAbs 177Lu-omburtamab-DTPA for the Treatment of Patients with Medulloblastoma Receives Positive Opinion on Orphan Medicinal Product Designation by EMA GlobeNewswire
Jun-23-21 09:00AM	Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma GlobeNewswire
Jun-22-21 06:54AM	Reflecting on Y-mAbs Therapeutics' (NASDAQ:YMAB) Share Price Returns Over The Last Year Simply Wall St. -7.48%
Jun-04-21 09:05AM	Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma GlobeNewswire
09:00AM	Y-mAbs Announces Update on Omburtamab for DIPG GlobeNewswire
May-20-21 12:30PM	Y-mAbs Signs Antibodies Distribution Deal With Adium; Street Says Buy SmarterAnalyst +7.42%
May-19-21 04:01PM	Y-mAbs Enters into Exclusive Distribution Agreement with Adium Pharma S.A. for DANYELZA® (naxitamab-gqgk) and Omburtamab in Latin America GlobeNewswire
May-13-21 09:00AM	Y-mAbs Announces Update on SADA Technology GlobeNewswire
May-07-21 07:15AM	Y-mAbs Therapeutics, Inc. to Host Earnings Call ACCESSWIRE +19.37%
May-06-21 05:50PM	YmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings Estimates Zacks
04:01PM	Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments GlobeNewswire
Apr-29-21 04:01PM	Y-mAbs to Announce First Quarter 2021 Financial and Operating Results on May 6, 2021 GlobeNewswire
09:00AM	Y-mAbs Announces Data to be Presented at 2021 ASCO Annual Meeting GlobeNewswire
Apr-27-21 04:01PM	Y-mAbs Submits Omburtamab Marketing Authorization Application to the European Medicines Agency GlobeNewswire
Apr-23-21 07:27AM	When Will Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Breakeven? Simply Wall St.
Apr-20-21 12:18PM	Y-mAbs Asked To Submit Additional Granularity Of Data For Omburtamab In Nerve Tissue Cancer Benzinga
09:00AM	Y-mAbs Provides Regulatory Update on Omburtamab GlobeNewswire
Apr-12-21 09:00AM	Y-mAbs Announces GPA33-SADA Data Presented at AACR GlobeNewswire
Apr-09-21 10:24AM	JPMorgan Says These 2 Stocks Could Surge Over 80% TipRanks -7.41%
Feb-28-21 11:46PM	Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Analysts Are Reducing Their Forecasts For This Year Simply Wall St.
Feb-26-21 06:45AM	Y-mAbs Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-25-21 04:01PM	Y-mAbs Announces 2020 Financial Results and Recent Corporate Developments GlobeNewswire -7.73%
04:50AM	Could The Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Ownership Structure Tell Us Something Useful? Simply Wall St.
Feb-22-21 04:01PM	Y-mAbs Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire -5.37%
Feb-19-21 09:00AM	Y-mAbs to Announce 2020 Financial and Operating Results on February 25, 2021 GlobeNewswire
Feb-18-21 05:20AM	Y-mAbs Therapeutics Raises $100M Via Equity To Fund Commercial Rollout Of Neuroblastoma Med Benzinga
Feb-17-21 07:14PM	Y-mAbs Announces Pricing of Public Offering of Common Stock GlobeNewswire -8.98%
Feb-16-21 04:01PM	Y-mAbs Announces Proposed Public Offering of Common Stock GlobeNewswire
Jan-06-21 09:00AM	Y-mAbs Therapeutics to Present At 39th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-20 09:00AM	Y-mAbs Announces Sale of Priority Review Voucher GlobeNewswire -5.27%
Dec-18-20 09:05AM	Y-mAbs Signs License Agreement with SciClone for DANYELZA® (naxitamab-gqgk) and Omburtamab in China GlobeNewswire
09:00AM	Y-mAbs Signs Distribution Agreement with Swixx for DANYELZA® (naxitamab-gqgk) and Omburtamab in Eastern Europe GlobeNewswire
Dec-16-20 09:00AM	Y-mAbs Announces Pipeline Update GlobeNewswire
Dec-10-20 04:50PM	Is YMAB A Good Stock To Buy Now? Insider Monkey
Dec-09-20 09:00AM	Y-mAbs Announces Update on DANYELZA® (naxitamab-gqgk) at ESMO GlobeNewswire
Dec-07-20 09:00AM	Y-mAbs to Host Virtual Research & Development Day on Wednesday, December 16 GlobeNewswire
Dec-04-20 12:06PM	Insider Sells Y-mAbs Therapeutics Stock Benzinga
09:00AM	Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel GlobeNewswire
Nov-25-20 05:02PM	FDA Approves Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of Neuroblastoma GlobeNewswire
Nov-19-20 09:00AM	Y-mAbs Announces Update on Omburtamab in DIPG GlobeNewswire
Nov-06-20 04:01PM	YmAbs Therapeutics, Inc. (YMAB) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 04:01PM	Y-mAbs Announces Third Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
Oct-29-20 09:00AM	Y-mAbs to Announce Third Quarter 2020 Financial and Operating Results on November 5, 2020 GlobeNewswire
Oct-28-20 03:02PM	We're Not Very Worried About Y-mAbs Therapeutics' (NASDAQ:YMAB) Cash Burn Rate Simply Wall St.
Oct-26-20 09:10AM	Y-mAbs Announces FDA Clearance of IND for Lutetium-177 Labeled Omburtamab Antibody for Adult Indications GlobeNewswire
Oct-16-20 09:00AM	Y-mAbs Announces Update on Naxitamab and Omburtamab in Neuroblastoma GlobeNewswire
Oct-14-20 09:00AM	Y-mAbs Announces FDA Clearance of IND for its Lutetium-177 Labeled Omburtamab Antibody GlobeNewswire
Oct-09-20 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Evolus, Lizhi, Iovance Biotherapeutics, and Y-mAbs Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire
Oct-08-20 05:34PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Y-mAbs Therapeutics, Inc. - YMAB PR Newswire
01:05PM	Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Y-mAbs Therapeutics, Inc. (YMAB) Investigation ACCESSWIRE
Oct-07-20 09:00AM	Y-mAbs Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA GlobeNewswire +7.45%
Oct-06-20 08:24AM	The Daily Biotech Pulse: Pfizer, BioNTech Begin European Filing For Coronavirus Vaccine, Y-mAbs BLA Rejected, GlycoMimetics Granted Rare Pediatric Disease Designation Benzinga -8.56%
Oct-05-20 04:01PM	Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma GlobeNewswire +7.28%
Aug-06-20 04:01PM	Y-mAbs Announces Second Quarter 2020 Financial Results and Recent Corporate Developments GlobeNewswire
09:00AM	Y-mAbs Announces Completion of Submission of Omburtamab Biologics License Application to FDA GlobeNewswire
Aug-04-20 09:00AM	Y-mAbs to Announce Second Quarter 2020 Financial and Operating Results on August 6, 2020 GlobeNewswire
Jul-27-20 04:01PM	Y-mAbs Announces Data to be Presented at 2020 SIOP GlobeNewswire +6.46%
Jul-14-20 09:00AM	Y-mAbs Announces Update on SADA Technology and New Preclinical SADA Construct GlobeNewswire
Jul-05-20 03:05PM	Y-mAbs Therapeutics, Inc. (YMAB): Are Hedge Funds Right About This Stock? Insider Monkey
Jun-30-20 04:01PM	Y-mAbs Announces Initiation of Submission of Omburtamab Rolling Biologics License Application to the FDA GlobeNewswire -5.41%
Jun-02-20 09:00AM	Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza (naxitamab) for the Treatment of Neuroblastoma for Priority Review GlobeNewswire
May-22-20 11:58AM	Should You Own This Sleeper Biotech Stock? Motley Fool

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kruse Bo	EVP, CFO, Secretary & Treas.	Feb 22	Sale	7.85	4,000	31,400	181,077	Feb 23 05:15 PM
Gad Thomas	See remarks	Feb 09	Sale	6.96	64,276	447,117	565,032	Feb 09 06:59 PM
Gad Thomas	See remarks	Feb 08	Sale	7.01	125,863	882,891	629,308	Feb 09 06:59 PM
Gad Thomas	See remarks	Feb 07	Sale	7.59	91,031	691,180	755,171	Feb 09 06:59 PM
Kruse Bo	EVP, CFO, Secretary & Treas	Feb 04	Sale	7.97	4,000	31,880	185,077	Feb 07 05:16 PM
Gad Thomas	See remarks	Feb 04	Sale	7.70	101,104	778,531	846,202	Feb 07 05:15 PM
Gad Thomas	See remarks	Feb 03	Sale	7.90	35,060	277,027	947,306	Feb 07 05:15 PM
Gad Thomas	See remarks	Feb 01	Option Exercise	2.00	8,000	16,000	58,000	Feb 03 05:00 PM
Gad Thomas	See remarks	Feb 01	Sale	10.15	8,000	81,161	50,000	Feb 03 05:00 PM
Gad Thomas	See remarks	Jan 24	Sale	10.63	88,055	936,412	982,366	Jan 26 05:09 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Jan 24	Sale	9.84	4,000	39,360	189,077	Jan 25 05:01 PM
Gad Thomas	See remarks	Jan 21	Sale	10.75	70,318	755,815	1,070,421	Jan 24 05:39 PM
Gad Thomas	See remarks	Jan 20	Sale	11.33	112,767	1,277,289	1,140,739	Jan 24 05:39 PM
Gad Thomas	See remarks	Jan 19	Sale	10.89	69,414	756,092	1,253,506	Jan 20 05:13 PM
Gad Thomas	See remarks	Jan 18	Option Exercise	2.00	8,000	16,000	58,000	Jan 20 05:13 PM
Gad Thomas	See remarks	Jan 18	Sale	11.46	400	4,584	1,322,920	Jan 20 05:13 PM
Gad Thomas	See remarks	Jan 18	Sale	11.54	8,000	92,314	50,000	Jan 20 05:13 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Jan 04	Sale	17.12	4,000	68,480	193,077	Jan 05 05:15 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Dec 22	Sale	16.36	4,000	65,440	197,077	Dec 23 04:55 PM
Gad Thomas	See remarks	Dec 07	Sale	17.58	10,000	175,832	1,383,320	Dec 08 05:18 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Dec 06	Sale	16.35	4,000	65,400	201,077	Dec 07 05:16 PM
Gad Thomas	See remarks	Dec 06	Sale	16.48	44,000	725,242	1,393,320	Dec 08 05:18 PM
Gad Thomas	See remarks	Nov 30	Sale	17.06	25,170	429,458	1,437,320	Dec 01 05:15 PM
Gad Thomas	See remarks	Nov 29	Sale	17.16	22,437	385,026	1,462,490	Dec 01 05:15 PM
Gad Thomas	See remarks	Nov 23	Option Exercise	2.00	50,000	100,000	100,000	Nov 26 05:33 PM
Gad Thomas	See remarks	Nov 23	Sale	17.06	50,000	852,850	50,000	Nov 26 05:33 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Nov 22	Sale	18.09	4,000	72,360	205,077	Nov 23 05:06 PM
Gad Thomas	See remarks	Nov 16	Sale	19.33	4,000	77,302	1,484,927	Nov 18 05:18 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Nov 04	Sale	27.54	4,000	110,160	209,077	Nov 05 05:16 PM
Gad Thomas	See remarks	Oct 29	Sale	24.82	4,000	99,261	1,488,927	Nov 01 05:15 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Oct 22	Sale	25.94	4,000	103,760	213,077	Oct 26 06:04 PM
Gad Thomas	See remarks	Oct 15	Sale	27.20	4,000	108,799	1,492,927	Oct 19 05:17 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Oct 04	Sale	28.78	4,000	115,120	217,077	Oct 05 05:16 PM
Gad Thomas	See remarks	Sep 30	Sale	28.26	4,000	113,054	1,496,927	Oct 04 05:17 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Sep 22	Sale	30.82	4,000	123,280	221,077	Sep 23 05:15 PM
Gad Thomas	See remarks	Sep 15	Sale	33.64	4,000	134,579	1,500,927	Sep 17 05:20 PM
Gad Thomas	See remarks	Sep 07	Option Exercise	2.00	50,000	100,000	50,000	Sep 07 05:30 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Sep 07	Sale	32.03	4,000	128,120	225,077	Sep 08 05:31 PM
Gad Thomas	See remarks	Sep 02	Sale	33.18	50,000	1,658,915	1,504,927	Sep 07 05:30 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Aug 23	Sale	28.60	4,000	114,400	229,077	Aug 24 05:02 PM
Gad Thomas	See remarks	Aug 17	Sale	28.96	1,779	51,527	1,554,927	Aug 17 06:32 PM
Gad Thomas	See remarks	Aug 16	Sale	29.30	26,111	765,071	1,556,706	Aug 17 06:32 PM
Gad Thomas	See remarks	Aug 13	Sale	31.01	1,110	34,426	1,582,817	Aug 17 06:32 PM
Rajah Vignesh	SVP & CMO	Aug 12	Buy	29.95	1,374	41,147	3,071	Aug 13 05:41 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Aug 04	Sale	33.72	4,000	134,880	233,077	Aug 05 05:20 PM
Gad Thomas	See remarks	Aug 03	Sale	33.73	4,000	134,927	1,583,927	Aug 05 05:18 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Jul 22	Sale	34.50	4,000	138,000	237,077	Jul 26 06:19 AM
Gad Thomas	See remarks	Jul 20	Sale	32.47	4,000	129,875	1,587,927	Jul 21 06:56 PM
Gad Thomas	See remarks	Jul 07	Sale	31.87	4,000	127,465	1,591,927	Jul 08 05:16 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Jul 06	Sale	34.15	4,000	136,600	241,077	Jul 07 06:00 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Jun 22	Sale	36.17	4,000	144,680	245,077	Jun 23 04:30 PM
Gad Thomas	See remarks	Jun 14	Sale	35.80	4,000	143,217	1,599,927	Jun 15 05:06 PM
WG Biotech ApS	Director	Jun 10	Sale	36.15	11,229	405,971	4,178,456	Jun 11 05:01 PM
Wedell-Wedellsborg Johan	Director	Jun 10	Sale	36.15	11,229	405,971	4,178,465	Jun 11 05:00 PM
Wedell-Wedellsborg Johan	Director	Jun 09	Sale	36.19	116,700	4,223,116	4,189,694	Jun 10 06:35 PM
WG Biotech ApS	Director	Jun 09	Sale	36.19	116,700	4,223,116	4,189,694	Jun 10 07:00 PM
WG Biotech ApS	Director	Jun 08	Sale	35.28	33,300	1,174,694	4,306,394	Jun 10 07:00 PM
Wedell-Wedellsborg Johan	Director	Jun 08	Sale	35.28	33,300	1,174,694	4,306,394	Jun 10 06:35 PM
WG Biotech ApS	10% Owner	Jun 07	Sale	34.15	72,400	2,472,583	4,339,694	Jun 09 06:51 PM
Wedell-Wedellsborg Johan	Director	Jun 07	Sale	34.15	72,400	2,472,583	4,339,694	Jun 09 06:49 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	Jun 04	Sale	33.48	4,000	133,920	249,077	Jun 07 04:30 PM
WG Biotech ApS	10% Owner	Jun 04	Sale	34.03	3,841	130,704	4,412,094	Jun 07 04:30 PM
Wedell-Wedellsborg Johan	Director	Jun 04	Sale	34.03	3,841	130,704	4,412,094	Jun 07 04:31 PM
Wedell-Wedellsborg Johan	Director	Jun 03	Sale	33.19	30,666	1,017,670	4,415,935	Jun 07 04:31 PM
WG Biotech ApS	10% Owner	Jun 03	Sale	33.19	30,666	1,017,670	4,415,935	Jun 07 04:30 PM
WG Biotech ApS	10% Owner	Jun 01	Sale	35.57	6,864	244,173	4,446,601	Jun 02 04:31 PM
Wedell-Wedellsborg Johan	Director	Jun 01	Sale	35.57	6,864	244,173	4,446,601	Jun 02 04:32 PM
Wedell-Wedellsborg Johan	Director	May 28	Sale	36.34	25,000	908,475	4,453,465	Jun 02 04:32 PM
WG Biotech ApS	10% Owner	May 28	Sale	36.34	25,000	908,475	4,453,465	Jun 02 04:31 PM
Gad Thomas	See remarks	May 28	Sale	36.95	4,000	147,813	1,603,927	Jun 01 04:32 PM
Kruse Bo	EVP, CFO, Secretary & Treas.	May 24	Sale	35.61	4,000	142,440	253,077	May 26 04:33 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience